Pharmacology, Receptor, Stereochemistry, Biochemistry and Immune system are his primary areas of study. The various areas that Sander G. Mills examines in his Pharmacology study include Sphingosine-1-phosphate receptor, Asthma, Morpholine and Migraine. His Receptor research incorporates elements of Biological activity, Endocrinology and Trifluoromethyl.
Sander G. Mills interconnects Antagonist and Chemokine receptor, Chemokine receptor activity in the investigation of issues within Stereochemistry. His Immune system research includes themes of Tissue transplant and Bone marrow. As a part of the same scientific study, he usually deals with the Piperidine, concentrating on CCR5 receptor antagonist and frequently concerns with Chemical synthesis.
His primary scientific interests are in Stereochemistry, Pharmacology, Receptor, Chemical synthesis and Tachykinin receptor. His Stereochemistry research is multidisciplinary, incorporating perspectives in Antagonist and CCR5 receptor antagonist, Chemokine receptor. Sander G. Mills has included themes like Asthma and Migraine in his Pharmacology study.
His Receptor research integrates issues from Endocrinology, Immune system and Bone marrow. His Chemical synthesis research incorporates themes from Selectivity, Structure–activity relationship, Moiety and Carboxamide. Sander G. Mills combines subjects such as Combinatorial chemistry, Morpholine, Active ingredient and Calcium channel with his study of Tachykinin receptor.
Sander G. Mills spends much of his time researching Stereochemistry, Receptor, Chemical synthesis, Pharmacology and Antagonist. His Stereochemistry study integrates concerns from other disciplines, such as CCR2, Structure–activity relationship and Trifluoromethyl. As part of his studies on Receptor, he often connects relevant subjects like Endocrinology.
His research in Chemical synthesis intersects with topics in Agonist, Biological activity, Selectivity and Cyclopentane. In his study, Active ingredient is strongly linked to Tachykinin receptor, which falls under the umbrella field of Pharmacology. His biological study spans a wide range of topics, including Reductase and Combination therapy.
The scientist’s investigation covers issues in Stereochemistry, Agonist, Chemical synthesis, Receptor and CCR2. His Stereochemistry research is multidisciplinary, incorporating elements of Ether, Morpholine, Tertiary amine and NK1 receptor antagonist. The study incorporates disciplines such as Pharmacokinetics and Insulin in addition to Agonist.
His work deals with themes such as Selectivity, Transplantation and Sphingosine-1-phosphate receptor, which intersect with Chemical synthesis. The CCR2 study combines topics in areas such as CC chemokine receptors, Antagonist, Trifluoromethyl and Carboxamide. His biological study spans a wide range of topics, including Diabetes mellitus and Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Distinct Mechanism for Antidepressant Activity by Blockade of Central Substance P Receptors
Mark S. Kramer;Neal Cutler;John Feighner;Ram Shrivastava.
Science (1998)
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes
M. Forrest;S.-Y. Sun;R. Hajdu;J. Bergstrom.
Journal of Pharmacology and Experimental Therapeutics (2004)
Chemistry of tricarbonyl hemiketals and application of Evans technology to the total synthesis of the immunosuppressant (-)-FK-506
Todd K. Jones;Robert A. Reamer;Richard Desmond;Sander G. Mills.
Journal of the American Chemical Society (1990)
Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist
J. J. Hale;S. G. Mills;M. Maccoss;P. E. Finke.
Journal of Medicinal Chemistry (1998)
Src kinase inhibitor compounds
Julianne A. Hunt;Sander G. Mills;Peter J. Sinclair;Dennis M. Zaller.
(2000)
Morpholine and thiomorpholine tachykinin receptor antagonists
Conrad P. Dorn;Paul E. Finke;Jeffrey J. Hale;Malcolm MacCoss.
(1993)
Total synthesis of immunosuppressant (-)-FK-506
Todd K. Jones;S. G. Mills;R. A. Reamer;D. Askin.
Journal of the American Chemical Society (1989)
Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Carina P. Tan;Yue Feng;Yun Ping Zhou;George J. Eiermann.
Diabetes (2008)
Pyrrolidine modulators of chemokine receptor activity
Charles Caldwell;Kevin T. Chapman;Jeffrey Hale;Dooseop Kim.
(2000)
Selective s1p1/edg1 receptor agonists
George A. Doherty;Michael J. Forrest;Richard Hajdu;Jeffrey J. Hale.
(2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
MSD (United States)
MSD (United States)
MSD (United States)
MSD (United States)
MSD (United States)
MSD (United States)
MSD (United States)
MSD (United States)
Scripps Research Institute
MSD (United States)
Shanghai Jiao Tong University
Arizona State University
Amazon (United States)
Chongqing Jiaotong University
Max Delbrück Center for Molecular Medicine
University College London
University of Western Ontario
Washington University in St. Louis
University of Poitiers
IHE Delft Institute for Water Education
University of Melbourne
Cedars-Sinai Medical Center
Queensland University of Technology
New York University
University of Girona
Icahn School of Medicine at Mount Sinai